Exposure-based psychological interventions currently represent the empirically best established first line form of cognitive-behavioural therapy for all types of anxiety disorders. Although shown to be highly effective in both randomized clinical and other studies, there are important deficits: (1) the core mechanisms of action are still under debate, (2) it is not known whether such treatments work equally well in all forms of anxiety disorders, including comorbid diagnoses like depression, (3) it is not known whether an intensified treatment with more frequent sessions in a shorter period of time provides better outcome than distributed sessions over longer time intervals. This paper reports the methods and design of a large-scale multicentre randomized clinical trial (RCT) involving up to 700 patients designed to answer these questions.
1 | INTRODUCTION
| Exposure therapy for anxiety disorders
Exposure-based cognitive-behavioural therapies (CBTs) are currently the most effective interventions for the treatment of anxiety disorders [ADs; Bandelow et al., 2014 ; National Institute for Health and Clinical Excellence (NICE), 2011, 2013] . Several meta-analyses of randomized clinical trials (RCTs) (Butler, Chapman, Forman, & Beck, 2006; Hofmann & Smits, 2008; Norton & Price, 2007) have shown large and long-term effects for various ADs such as panic disorder and agoraphobia (Mitte, 2005; Sánchez-Meca, Rosa-Alcázar, Marín-Martí-nez, & Gómez-Conesa, 2010) , social anxiety disorder (Mayo-Wilson et al., 2014) , generalized anxiety disorder, or specific phobias (Wolitzky-Taylor, Horowitz, Powers, & Telch, 2008) , with exposure being most often conceived as the central principle of change (Lohr, Lilienfeld, & Rosen, 2012; Neudeck & Wittchen, 2012) . Despite the consistent evidence for the overall efficacy of exposure-based CBT, several research questions remain.
First, CBT is an umbrella term describing an intervention package that includes various components such as psychoeducation, cognitive restructuring, exposure-based interventions applied in situ, in sensu or in virtual reality contexts. These components are supposed to differentially target specific dysfunctional domains of the patient's symptomatology. Considerable variation in CBTs exists further by type of AD, as well as by form and intensity of cognitive-emotional and behavioural intervention components, making it difficult to pinpoint their respective effect. Thus, the core active ingredients of CBTs that promote change and the mechanisms involved in therapeutically induced change in specific ADs remain difficult to determine. Second, not all patients benefit equally well. Treatment attrition rates in AD psychotherapy studies range around 16-31% (Fernandez et al., 2015; Taylor, Abramowitz, & McKay, 2012) . Of those who commence therapy, 40-47% fail to remit or relapse after successful treatment (Loerinc et al., 2015) . Thus, the question arises whether augmenting central treatment components leads to better and more stable outcomes.
In the past, various mechanisms have been identified as possible mechanisms underlying exposure-based CBT, including within-and between-session habituation (Foa & Kozak, 1986) , counterconditioning (Wolpe, 1995) , or neurotrophic factors (Ströhle et al., 2010) . More recent evidence points to extinction as the central process that underlies the reduction of fear (Milad & Quirk, 2012; Vervliet, Craske, & Hermans, 2013 ).
| Experimental investigation of extinction
The term "extinction" descends from paradigms of Pavlovian conditioning and is commonly used in various ways; (1) to describe the experimental procedure during which a conditioned stimulus (CS+) that has previously been paired with the unconditioned stimulus (US) is now presented without the US; (2) to describe the result of the procedure, the reduction of the fear response that can be observed even after days (long-term extinction); and (3) to describe the associative neuronal learning as well as memory process that underlies the reduction of the fear response. Here, the term extinction training will be used to describe the experimental procedure, fear reduction will be used to describe the decrease of the fear response, and extinction to describe the learning process that underlies the observed fear reduction (see Myers & Davis, 2007) . Supporting the clinical relevance of extinction, studies indicated that patients with ADs show increased fear responses to the CS+ during extinction training compared to healthy controls (Duits et al., 2015; Lissek et al., 2005) . This deficit in fear extinction may contribute to the intensity, generalization, and persistence of pathological anxiety. Deficits in extinction have also been associated with a subsequent onset of ADs (Lommen, Engelhard, Sijbrandij, van den Hout, & Hermans, 2013) and with non-response to exposure-based CBT (Fullana et al., 2016) . Thus, impaired extinction may represent a central mechanism for both the development of ADs and their treatment (Craske et al., 2008) . Understanding how extinction can be facilitated during exposure-based interventions might be crucial to optimize the effects of exposure therapy.
Phenomena such as reinstatement of fear -i.e. fast recovery of fear during mere presentations of the US after extinction -demonstrate that the CS-US associations are not simply forgotten (for a review see Vervliet et al., 2013) . Instead, the individual has to actively learn that the feared cue is no longer followed by the aversive consequences. For example, a patient with agoraphobia who is afraid to faint (US) when using public transportation (CS+) holds the fear-evoking or excitatory association "public transport -fainting". If, however, he uses a bus but does not faint, an additional inhibitory association ("bus -no fainting") is formed, that will reduce the fear response when the CS memory in a bus) is activated. The initial excitatory association is not erased but rather modulated by the inhibitory association that is also stored in memory. Depending on strength and diversity of excitatory associations, fear memories may be retrieved even after successful extinction (Bouton, 2004) . Thus, even after response to exposurebased treatment, fear and anxious responses may return. Strengthening the inhibitory non-fear associations may attenuate this return of fear and result in better long-term treatment outcome.
| Clinical translation of extinction
Translating the extinction model to clinical practice, several behavioural strategies have been suggested to enhance exposure (Pittig, van den Berg, & Vervliet, 2016) . Central to these strategies is to "put the patient's central concerns to a test", because new, inhibitory learning is initiated when a prediction error occurs (Rescorla & Wagner, 1972) : extinction is facilitated if the individuals' central concern is violated by the exposure experience. To that end, the patients' central concern needs to be precisely formulated prior to exposure and exercises individually designed to allow patients to test and disconfirm their predictions (Craske, Treanor, Conway, Zbozinek, & Vervliet, 2014) . To increase the positive prediction error, safety signals, avoidance behaviours and other control strategies need to be abolished.
Here, patients are instructed to renounce any behaviour or circumstance that might decrease their central concern (e.g. conducting exposure without the presence of an accompanying person, which is believed to prevent negative consequences). Furthermore, variation strategies such as variation of stimulus and context properties (Bouton, 2004) or compound or deepened extinction (Culver, Vervliet, & Craske, 2015) have been experimentally investigated (for a detailed description see Craske et al., 2014; Pittig et al., 2015) .
Another enhancement strategy targets the timing or spacing between exposure exercises to augment extinction. While short-term extinction may be accelerated by shortening intervals between exposure sessions (Orinstein, Urcelay, & Miller, 2010; Tsao & Craske, 2000) , this might attenuate long-term learning effects (Rowe & Craske, 1998) .
Long-term learning might instead be augmented by expanding the temporal spacing of exposure exercises (Bjork & Bjork, 2006) . Thus, an intensified psychological treatment may combine temporally massed exposure followed by a gradual extension of intervals may result in optimal long-term learning and even in shorter treatment durations. 
| Sampling and eligibility
Target sample size to be included are N = 700 patients with primary DSM-5 anxiety disorders (Wittchen, Heinig, & Beesdo-Baum, 2014) .
Participants are primarily recruited from university outpatient clinics at each site. Participants are screened (age, primary anxiety complaints, availability and prior treatment, as described later) and invited for informed consent and a subsequent diagnostic baseline assessment to inspect eligibility criteria (see Table 1 ). Patients with acute anxietyrelated pharmacotherapy [e.g. selective serotonin reuptake inhibitors (SSRIs), benzodiazepines] are excluded, whereas maintenance therapy (> three months and stable) is allowed if patients still meet inclusion criteria. Medication is kept stable during therapy. Concomitant psychotherapy is not allowed. If a patient decides to stop pharmacotherapy or a concomitant CBT prior to inclusion, a waiting period of two to three months is set. Medical relative contraindications involve conditions that impede thorough exposure, e.g. cardiovascular diseases, autoimmune diseases or pregnancy. As prior research shows that CBT for ADs also results in decreased negative affect and depression (Emmrich et al., 2012; Olatunji, Cisler, & Tolin, 2010) , patients with comorbid depression are explicitly included.
Eligible patients are randomized to one of the two conditions. Randomization is performed using DatInf Randlist (version 1.2). A two-stage randomization procedure ensures that no single person is able to foresee group assignment. Blinding of patients and therapists is not feasible in psychotherapy studies.
Sample size was calculated based on the SIGH-A total score. For patients in IPI, a reduction of the primary outcome by 12 points at the end of treatment is expected, compared to a reduction by 10 (1) current primary DSM-IV/5 anxiety disorder: panic disorder (PD), agoraphobia (AG), social anxiety disorder (SAD), specific phobias (SP) (2) outpatients (3) age: 15-70 years (4) severity at baseline: SIGH-A ≥ 19 and CGI ≥ 4 (5) written informed consent (6) able to attend all therapy sessions on his/her own or accompanied by significant other (7) sufficient German language competence (1) any DSM-IV/5 psychotic disorder, primary mood disorders (bipolar I, recurrent or chronic major depression) (2) current substance use disorder (without nicotine dependence) (3) concomitant psychological/psychiatric treatment (4) acute suicidality (5) general medical contraindications (6) mono-symptomatic specific phobia Note: SIGH-A, Structured Interview Guide for the Hamilton Anxiety Rating Scale (Shear et al., 2001 ); CGI, Clinical Global Impression Scale (Guy, 1976) .
FIGURE 1 RCT design, study visits and intersection with add-on projects points for patients in TAU. Using a power of 80%, a test significance level of alpha =5%, a standard deviation of 10 points and a one-sided t-test to detect differences between the IPI and TAU group, a total of 310 patients are needed per group, i.e. 620 patients are planned to be analysed (see Figure 2) . Based on previous similar trials (Gloster et al., 2009 ) drop-out rates during treatment of 10 to 15% are expected.
| Diagnostic domains and instruments
Primary efficacy endpoint is the clinician-rated SIGH-A (see Table 2 and Supporting Information for description of the instruments). 
| Study personnel
Therapies are realized by certified study therapists who are stateexamined cognitive-behavioural psychotherapists or psychotherapy trainees in advanced stage of training. They receive a two-day practice-oriented training of the study manual. Therapists have to treat patients in both experimental groups to avoid therapist effects.
Certification requires implementation and video recording of one IPI therapy, which is evaluated based on five core treatment sequences. Session protocols are administered after each therapy session and include patients' ratings of therapy quality, homework compliance, therapy motivation and general health.
b Exposure protocols are administered before and after each exposure trial and include the tested central concern, prediction error, course of anxiety, safety behaviors and mood indicated by the patient as well as a success rating, typical problems, enhancement strategies and learning experience indicated by the therapist.
Note: SIGH-A, Structured Interview Guide for the Hamilton Anxiety Rating Scale (Shear et al., 2001) ; CGI, Clinical Global Impression Scale (Guy, 1976) ; CIDI (DIA-X), Computerized Version of the Munich Composite International Diagnostic Interview (Wittchen & Pfister, 1997) ; Cross-D, Cross-Cutting Dimensional Scale for anxiety disorders (ADs) (LeBeau et al., 2012) ; BSI, Brief Symptom Inventory (Derogatis & Spencer, 1993) ; BDI-II, Beck Depression Inventory-II (Beck, Steer, & Brown, 1996) ; ASI, Anxiety Sensitivity Inventory (Reiss, Peterson, Gursky, & McNally, 1986) ; PAS, Panic and Agoraphobia Scale (Bandelow, 1999) 
| Monitoring and quality assurance
Data management, including monitoring and validity checks, is effectuated by a central data management officer using the study software REDCap, a secure web application including an audit trail. All assessments and modifications are immediately accessible via web access.
At each participating centre an assigned data manager is responsible for online transmission of data and site specific quality assurance.
Supervision of data management according to GCP Guidelines All sites receive initial and regular site visits by study monitors to check protocol adherence. Protocol violations will be documented and lead to exclusion of patients, therapists or the centre.
| Feasibility
To ensure feasibility of the trial, a pilot study was run using a prelimi- 
| METHODS OF THE EXPERIMENTAL ADD-ON PROJECTS
There is substantial meta-analytic evidence that patients with ADs show slower and weaker fear reduction during extinction training compared to healthy controls (Duits et al., 2015) . These deficits also seem to exist prior to the development of pathological anxiety (Lommen et al., 2013) . However, it is unclear whether they are prevalent in all ADs -very few data are available for specific phobias and social anxiety disorder -and if there are disorder-specific deficits.
For example, patients with agoraphobia might show stronger deficits when aversive contexts are extinguished whereas patients with specific phobias might show more deficits in extinction of aversive cues. The question whether deficits in extinction processes predict therapy outcome has only recently be addressed (Hahn et al., 2015; Waters & Pine, 2016) and it is unknown if they are stable or are altered during psychotherapy. Duits, Cath, Heitland, and Baas (2016) retrospectively found no differences in extinction in treated AD compared to controls, but prospective evidence is lacking.
To target these questions, the RCT is coupled with experimental add-on projects implementing a laboratory-assessed extinction training prior to and after therapy. Extinction is examined using multi-level assessments involving verbal report, physiological and neural data. Further, (epi)genetic data and ecological momentary assessments are used to examine moderators and mediators of extinction.The main goals of the add-on projects are:
1. To study extinction as a potential mechanism of exposure on a phenotypic, psychophysiological and neural level.
2. To detect moderators and mediators of extinction on a phenotypic, behavioural and (epi)genetic level.
| Psychophysiological and neural markers of extinction
The psychophysiological and neural add-on projects examine extinction and reinstatement using a two-day experimental extinction training protocol in both experimental groups. During day one, one of two neutral facial stimuli (CS+) embedded in either blue or yellow background colour is followed by an aversive electric US during six of 10 presentations while the other stimulus (CS˗) is never paired with the US. Since the focus of the study is on extinction we want to make sure that each patient indeed will acquire a fear response. Therefore, we give an instruction prior to the acquisition phase stating which of the two facial stimuli would occasionally be followed by the aversive US and which one will not. On day two, extinction and reinstatement are tested during functional magnetic resonance imaging (fMRI). The paradigm starts with one re-acquisition trial followed by an extinction training during which both stimuli are presented again 20 times each without any presentation of the US. After presentation of three aversive US without any CS, 10 extinction trials for each CS will be presented to test the effect of reinstatement. Neural correlates of fear extinction, reinstatement and emotion processing are examined focussing on amygdala, (para-)hippocampal and anterior cingulate cortex (ACC) function (Lueken et al., 2013; Sehlmeyer et al., 2011) . The paradigm is repeated after psychotherapy, using two different faces to avoid re-acquisition. In addition, a paradigm on emotion processing; structural scans and a resting state examination are conducted in the fMRI scanner. To disentangle psychotherapy and memory effects, the paradigm is also applied in a healthy control group (n = 100). This is the first study investigating extinction and reinstatement via fMRI before and after exposure therapy.
Due to physical contraindications, lack of informed consent and other exclusion reasons a sample size of n = 300 patients is expected for the fMRI part of the study. Patients with fMRI-related contraindications will perform the paradigm on fear extinction and reinstatement on day two in the psychophysiological laboratory. In addition, these participants are asked to participate in a context conditioning experiment using a virtual reality paradigm on day two. In this paradigm, participants can enter one of two rooms from a corridor (ITI), and four aversive events (unpleasant scream) will occur in one room (context; CTX+) but not in the other (CTX˗). Immediately after acquisition, extinction of context anxiety will be investigated.
Different from other studies, this paradigm uses multiple measures of fear including verbal report of contingency expectancies, valence and arousal ratings, changes in measures of autonomic nervous system activity (i.e. heart rate, skin conductance) as well as fear potentiated startle -a low level brain stem measure modulated by subcortical structures (e.g. amygdala). These measures have been used extensively in prior research (for reviews see Duits et al., 2015; Hamm & Weike, 2005) . Main hypotheses are:
1. Extinction is impaired in ADs prior to therapy and will improve to a greater degree after IPI than TAU.
Extinction of contextual fear is impaired in ADs and will improve
to a greater degree after IPI than TAU. of the recruited patients could be included in the fMRI add-on project.
Additionally, 15 healthy control subjects have been investigated.
Psychophysiological markers of extinction were investigated in 71 patients (34.80%) during day two prior to therapy (only patients who did not take part in the fMRI assessment); 36 patients participated in the psychophysiological laboratory at post-assessment.
| (epi)genetic variation
ADs and components of fear conditioning are significantly genetically determined (Hettema, Annas, Neale, Kendler, & Fredrikson, 2003) . Several risk genes of anxiety and particularly extinction have been identified, with some of them also driving response to treatment (Stafford & Lattal, 2011) . Further, pilot studies suggest epigenetic mechanisms such as DNA methylation in the pathogenesis of anxiety and their reversibility by cognitive-behavioural psychotherapeutic interventions (Domschke et al., 2012; Ziegler et al., 2015 Ziegler et al., , 2016 . This subproject examines the role of genetic variation as well as DNA methylation as disease markers, predictors of therapy response and -in case of epigenetic mechanisms -as a potential correlate of extinction. All RCT patients will be analysed for DNA The rate of participation is thus 86.3%.
| Ecological momentary assessment
Clinical interviews and questionnaires in psychotherapy trials are criticized for a potential lack of ecological validity due to retrospective recall, context effects or the averaging of dynamic phenomena.
Actography and ecological momentary assessment (EMA) -the collection of data objective and subjective parameters over the day in the patient's natural environment -are methods to obtain more ecologically valid data. This technology has already been used successfully in AD research (Walz, Nauta, & aan het Rot, 2014) and is here used to examine whether clinical outcome is associated with changes in everyday life. Hypotheses are:
1. After exposure-based treatment, AD patients will report more positive emotionality, social activity, higher locomotor and geographic activity [determined by global positioning system (GPS)]
and less impairment by anxiety in their everyday living context.
Differences will be more pronounced in IPI than in TAU.
2. During the individualized exposure phase, patients in IPI will engage more intensively in exposure exercises and experience greater prediction error compared to patients in TAU.
The EMA during the exposure phase contains questions on the preparation, specific expectancies, emotions and evaluations of exposure exercises. Most importantly, expectancies are assessed multiple times before and after each exercise to evaluate the course of the expectancy of central concerns. This allows to examine if prediction error is constant once it has been experienced.
| TRANSFER INTO THE ROUTINE PROVIDER SYSTEM
Multiple barriers have been proposed to explain why exposure-based interventions remain underused or inappropriately delivered in routine care. Systematic research on this issue, however, is largely lacking.
Therefore, all major stakeholder groups -patients, providers, professional associations and insurances -are involved to assess treatment-specific beliefs and concerns and to improve transfer of interventions. Using a stepwise approach, there are firstly surveys carried out among practitioners to assess current practice of exposure, subjective barriers of practitioners, and attitudes towards exposure.
Secondly, a joint campaign of stakeholders is initiated to promote changes in service delivery, involving discussion forums for practitioners with other stakeholders, training activities by the study clinicians and public outreach such as publications in journals targeting practitioners.
It is hypothesized that continuous involvement of stakeholders will help to clarify barriers and change misconceptions and reservations against exposure-based treatments. As a result, it is expected that practitioners will show a more frequent and adequate use of exposure-based interventions in those regions where translational activities were carried out compared to regions without such activities. By straining translational activities from the beginning of the project, the consortium avoids typical vices in clinical research. 
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